Puma Biotechnology will host a conference call to discuss first quarter financial results

Puma Biotechnology will host a conference call to discuss first quarter financial results

LOS ANGELES, April 21, 2022– (BUSINESS WIRE) – Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will hold a conference call at 1:30 pm PDT / 4:30 pm EDT Thursday, May 5, 2022, following the release of the financial results of the first quarter 2022.

You can access the call by dialing (866) 682-6100 (national) or (862) 298-0702 (international). Please call at least 10 minutes in advance and inform the operator that you wish to attend the “Puma Biotechnology Conference Call”. A live webcast of the conference call and presentation slides can be accessed in the Investors section of the Puma Biotechnology website at https://www.pumabiotechnology.com. A replay of the call will be available approximately one hour after the call is completed and will be archived on the Puma website for 90 days.

Information on Puma biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative products to improve cancer care. The Company licenses global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration (FDA) in 2017 for the extended adjuvant treatment of adult patients with HER2 overexpressed / amplified early stage breast cancer following adjuvant trastuzumab therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX received marketing authorization from the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2 overexpressed / amplified breast cancer who are less than one year old from completion of prior therapy. adjuvant based on trastuzumab. NERLYNX is a registered trademark of Puma Biotechnology, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220421005954/en/

Contacts

Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500
info@pumabiotechnology.com
ir@pumabiotechnology.com

David Schull, Russo Partners, +1 212 845 4200
david.schull@russopartnersllc.com

Leave a Comment

Your email address will not be published.